SIK2 restricts autophagic flux to support triple-negative breast cancer survival

Molecular and Cellular Biology

Volumn 36, Issue 24, 2016, Pages 3048-3057

  Maxfield, Kimberly E ^a,b,d   Macion, Jennifer ^b   Vankayalapati, Hariprasad ^c   Whitehurst, Angelique W ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Early Discovery and Medicinal Chemistry   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOPHAGY RELATED PROTEIN 5; CLAUDIN; MESSENGER RNA; PHOSPHOTRANSFERASE; SALT INDUCIBLE KINASE 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ATG5 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SALT-INDUCIBLE KINASE-2, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BREAST CARCINOGENESIS; CANCER SURVIVAL; CELL ACTIVITY; CELL DEATH; CELL LOSS; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; FEMALE; GENETIC TRANSFECTION; HEREDITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VIVO STUDY; LENTIVIRUS INFECTION; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEPLETION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE; TUMOR GROWTH; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; AUTOPHAGY; AUTOPHAGY-RELATED PROTEIN 5; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CLAUDINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM TRANSPLANTATION; PROTEIN-SERINE-THREONINE KINASES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85001133174     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00380-16     Document Type: Article

References (44)

1. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. 2010. American Society of Clinical Oncology/ College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795. http://dx.doi.org/10.1200/JCO.2009.25.6529.
2. Jahanzeb M. 2008. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 8:324-333. http://dx.doi.org/10.3816 /CBC.2008.n.037.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792 http://dx.doi.org/10.1056/NEJM200103153441101.
4. Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacon JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Segui-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, Lopez JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martin M, Perou CM, Alba E. 2014. Predicting response and survival in chemotherapytreated triple-negative breast cancer. Br J Cancer 111:1532-1541. http://dx.doi.org/10.1038/bjc.2014.444.
5. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. 2009. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7:4-13. http://dx.doi.org /10.3121/cmr.2008.825.
6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. 2000. Molecular portraits of human breast tumours. Nature 406:747-752. http://dx.doi.org/10.1038/35021093.
7. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. 2010. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68. http://dx.doi.org/10.1186/bcr2635.
8. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. 2011. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121:2750-2767. http://dx.doi.org/10.1172/JCI45014.
9. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515-527. http://dx.doi.org/10.1016/j.ccr.2006.10.008.
10. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad SciUSA98:10869-10874. http: //dx.doi.org/10.1073/pnas.191367098.
11. Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M, Perou CM. 2013. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat 142: 237-255. http://dx.doi.org/10.1007/s10549-013-2743-3.
12. Dentin R, Liu Y, Koo SH, Hedrick S, Vargas T, Heredia J, Yates J, III, Montminy M. 2007. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 449:366-369. http://dx.doi.org/10.1038 /nature06128.
13. Screaton RA, Conkright MD, Katoh Y, Best JL, Canettieri G, Jeffries S, Guzman E, Niessen S, Yates JR, III, Takemori H, Okamoto M, Montminy M. 2004. The CREB coactivator TORC2 functions as a calcium-and cAMP-sensitive coincidence detector. Cell 119:61-74. http://dx.doi.org /10.1016/j.cell.2004.09.015.
14. Itoh Y, Sanosaka M, Fuchino H, Yahara Y, Kumagai A, Takemoto D, Kagawa M, Doi J, Ohta M, Tsumaki N, Kawahara N, Takemori H. 2015. Salt-inducible kinase 3 signaling is important for the gluconeogenic programs in mouse hepatocytes. J Biol Chem 290:17879-17893. http://dx.doi.org/10.1074/jbc.M115.640821.
15. Nixon M, Stewart-Fitzgibbon R, Fu J, Akhmedov D, Rajendran K, Mendoza-Rodriguez MG, Rivera-Molina YA, Gibson M, Berglund ED, Justice NJ, Berdeaux R. 2016. Skeletal muscle salt inducible kinase 1 promotes insulin resistance in obesity. Mol Metab 5:34-46. http://dx.doi.org/10.1016/j.molmet.2015.10.004.
16. Park J, Yoon YS, Han HS, Kim YH, Ogawa Y, Park KG, Lee CH, Kim ST, Koo SH. 2014. SIK2 is critical in the regulation of lipid homeostasis and adipogenesis in vivo. Diabetes 63:3659-3673. http://dx.doi.org/10.2337/db13-1423.
17. Lombardi MS, Gillieron C, Dietrich D, Gabay C. 2016. SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype. J Leukoc Biol 99:711-721. http://dx.doi.org/10.1189/jlb.2A0715-307R.
18. Potts MB, Kim HS, Fisher KW, Hu Y, Carrasco YP, Bulut GB, Ou YH, Herrera-Herrera ML, Cubillos F, Mendiratta S, Xiao G, Hofree M, Ideker T, Xie Y, Huang LJ, Lewis RE, MacMillan JB, White MA. 2013. Using functional signature ontology (FUSION) to identify mechanisms of action for natural products. Sci Signal 6:ra90.
19. Sanosaka M, Fujimoto M, Ohkawara T, Nagatake T, Itoh Y, Kagawa M, Kumagai A, Fuchino H, Kunisawa J, Naka T, Takemori H. 2015. Salt-inducible kinase 3 deficiency exacerbates lipopolysaccharide-induced endotoxin shock accompanied by increased levels of pro-inflammatory molecules in mice. Immunology 145:268-278. http://dx.doi.org/10.1111 /imm.12445.
20. Sundberg TB, Choi HG, Song JH, Russell CN, Hussain MM, Graham DB, Khor B, Gagnon J, O'Connell DJ, Narayan K, Dancik V, Perez JR, Reinecker HC, Gray NS, Schreiber SL, Xavier RJ, Shamji AF. 2014. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proc Natl Acad Sci U S A 111:12468-12473. http://dx.doi.org /10.1073/pnas.1412308111.
21. Yang FC, Tan BC, Chen WH, Lin YH, Huang JY, Chang HY, Sun HY, Hsu PH, Liou GG, Shen J, Chang CJ, Han CC, Tsai MD, Lee SC. 2013. Reversible acetylation regulates salt-inducible kinase (SIK2) and its function in autophagy. J Biol Chem 288:6227-6237. http://dx.doi.org/10.1074 /jbc.M112.431239.
22. Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Australian Ovarian Cancer Study Group, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC, Jr. 2010. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18:109-121. http://dx.doi.org/10.1016/j.ccr.2010.06.018.
23. Bon H, Wadhwa K, Schreiner A, Osborne M, Carroll T, Ramos-Montoya A, Ross-Adams H, Visser M, Hoffmann R, Ahmed AA, Neal DE, Mills IG. 2014. Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer. Mol Cancer Res 13:620-635. http: //dx.doi.org/10.1158/1541-7786.MCR-13-0182-T.
24. Cheng H, Liu P, Wang ZC, Zou L, Santiago S, Garbitt V, Gjoerup OV, Iglehart JD, Miron A, Richardson AL, Hahn WC, Zhao JJ. 2009. SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal 2:ra35.
25. Clark K, MacKenzie KF, Petkevicius K, Kristariyanto Y, Zhang J, Choi HG, Peggie M, Plater L, Pedrioli PG, McIver E, Gray NS, Arthur JS, Cohen P. 2012. Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci U S A 109:16986-16991. http://dx.doi.org /10.1073/pnas.1215450109.
26. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. 2007. The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297-315. http: //dx.doi.org/10.1042/BJ20070797.
27. Gum RJ, McLaughlin MM, Kumar S, Wang Z, Bower MJ, Lee JC, Adams JL, Livi GP, Goldsmith EJ, Young PR. 1998. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem 273:15605-15610. http://dx.doi.org/10.1074/jbc.273.25.15605.
28. Wang Z, Canagarajah BJ, Boehm JC, Kassisa S, Cobb MH, Young PR, Abdel-Meguid S, Adams JL, Goldsmith EJ. 1998. Structural basis of inhibitor selectivity in MAP kinases. Structure 6:1117-1128. http://dx.doi.org/10.1016/S0969-2126(98)00113-0.
29. White E. 2015. The role for autophagy in cancer. J Clin Investig 125:42-46 http://dx.doi.org/10.1172/JCI73941.
30. Tang H, Sebti S, Titone R, Zhou Y, Isidoro C, Ross TS, Hibshoosh H, Xiao G, Packer M, Xie Y, Levine B. 2015. Decreased mRNA expression in human breast cancer is associated with estrogen receptor-negative subtypes and poor prognosis. EBioMedicine 2:255-263. http://dx.doi.org/10.1016/j.ebiom.2015.01.008.
31. Patel K, Foretz M, Marion A, Campbell DG, Gourlay R, Boudaba N, Tournier E, Titchenell P, Peggie M, Deak M, Wan M, Kaestner KH, Goransson O, Viollet B, Gray NS, Birnbaum MJ, Sutherland C, Sakamoto K. 2014. The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver. Nat Commun 5:4535.
32. Kim J, Kundu M, Viollet B, Guan KL. 2011. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13:132-141 http://dx.doi.org/10.1038/ncb2152.
33. Hara T, Takamura A, Kishi C, Iemura S, Natsume T, Guan JL, Mizushima N. 2008. FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells. J Cell Biol 181:497-510. http://dx.doi.org/10.1083/jcb.200712064.
34. Egan DF, Chun MG, Vamos M, Zou H, Rong J, Miller CJ, Lou HJ, Raveendra-Panickar D, Yang CC, Sheffler DJ, Teriete P, Asara JM, Turk BE, Cosford ND, Shaw RJ. 2015. Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates. Mol Cell 59:285-297. http://dx.doi.org/10.1016/j.molcel.2015.05.031.
35. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gelinas C, Fan Y, Nelson DA, Jin S, White E. 2006. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10:51-64. http://dx.doi.org/10.1016 /j.ccr.2006.06.001.
36. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, Kamphorst JJ, Chen G, Lemons JM, Karantza V, Coller HA, Dipaola RS, Gelinas C, Rabinowitz JD, White E. 2011. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 25:460-470. http://dx.doi.org/10.1101/gad.2016311.
37. Lock R, Kenific CM, Leidal AM, Salas E, Debnath J. 2014. Autophagydependent production of secreted factors facilitates oncogenic RASdriven invasion. Cancer Discov 4:466-479. http://dx.doi.org/10.1158 /2159-8290.CD-13-0841.
38. Hu YL, Jahangiri A, Delay M, Aghi MK. 2012. Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res 72:4294-4299. http://dx.doi.org/10.1158 /0008-5472.CAN-12-1076.
39. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B. 1999. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402:672-676. http://dx.doi.org/10.1038/45257.
40. Wei H, Wei S, Gan B, Peng X, Zou W, Guan JL. 2011. Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev 25:1510-1527. http://dx.doi.org/10.1101/gad.2051011.
41. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, Dipaola RS, Karantza-Wadsworth V, White E. 2009. Autophagy suppresses tumorigenesis through elimination of p62. Cell 137:1062-1075. http://dx.doi.org/10.1016/j.cell.2009.03.048.
42. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S, Lipton SA, Lu X, Madeo F, Malorni W, Mehlen P, Nunez G, Peter ME, Piacentini M, Rubinsztein DC, Shi Y, Simon HU, Vandenabeele P, White E, Yuan J, Zhivotovsky B, Melino G, Kroemer G. 2012. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 19:107-120. http://dx.doi.org/10.1038/cdd.2011.96.
43. Liu Y, Shoji-Kawata S, Sumpter RM, Jr, Wei Y, Ginet V, Zhang L, Posner B, Tran KA, Green DR, Xavier RJ, Shaw SY, Clarke PG, Puyal J, Levine B. 2013. Autosis is a Na,K-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxiaischemia. Proc Natl Acad Sci U S A 110:20364-20371. http://dx.doi.org /10.1073/pnas.1319661110.
44. Henriksson E, Sall J, Gormand A, Wasserstrom S, Morrice NA, Fritzen AM, Foretz M, Campbell DG, Sakamoto K, Ekelund M, Degerman E, Stenkula KG, Goransson O. 2015. SIK2 regulates CRTCs, HDAC4 and glucose uptake in adipocytes. J Cell Sci 128:472-486. http://dx.doi.org/10.1242/jcs.153932.